相似文献
1
Hepatitis B management: it is time to change the strategy.
Saudi J Gastroenterol. 2014 Nov-Dec;20(6):331-2. doi: 10.4103/1319-3767.145313.
2
[Optimized strategy: new concept in antiviral therapy for chronic hepatitis B].
Zhonghua Gan Zang Bing Za Zhi. 2012 Feb;20(2):82-5. doi: 10.3760/cma.j.issn.1007-3418.2012.02.002.
3
[A primer on the management of antiviral resistance in chronic hepatitis B].
Rev Med Suisse. 2009 Jan 21;5(187):203-4, 206-8,.
4
[Management of HBeAg negative chronic hepatitis B].
Zhonghua Gan Zang Bing Za Zhi. 2005 Jul;13(7):539.
5
[Monitoring and treatment strategy for chronic hepatitis B and antiviral resistant hepatitis B].
Korean J Gastroenterol. 2007 Jun;49(6):346-55.
6
[Management of chronic hepatitis B].
Rev Med Suisse. 2010 Jan 27;6(233):168-70, 172-3.
7
[Report of the Fifth Symposium on the Hotspots and Challenges in Research of Antiviral Therapy for Chronic Hepatitis B and Chronic Hepatitis C].
Zhonghua Gan Zang Bing Za Zhi. 2014 Jun;22(6):468-9.
8
[Latin American guideline for the management of chronic hepatitis B].
Acta Gastroenterol Latinoam. 2011 Dec;41(4):340-50.
9
[Optimal strategy for chronic hepatitis B patients receiving nucleos(t)ide analogue antiviral treatment].
Zhonghua Gan Zang Bing Za Zhi. 2011 Jun;19(6):408-11.
10
[Management of chronic viral hepatitis].
Rev Med Suisse. 2007 Jan 24;3(95):215, 217-8, 221-3.
本文引用的文献
1
Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
Saudi J Gastroenterol. 2014 Nov-Dec;20(6):350-5. doi: 10.4103/1319-3767.145320.
2
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
J Viral Hepat. 2015 Feb;22(2):85-93. doi: 10.1111/jvh.12313. Epub 2014 Sep 22.
3
SASLT practice guidelines for the management of hepatitis B virus.
Saudi J Gastroenterol. 2014 Jan-Feb;20(1):5-25. doi: 10.4103/1319-3767.126311.
4
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Can J Gastroenterol. 2012 Dec;26(12):917-38. doi: 10.1155/2012/506819.
5
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.
6
Treatment of chronic hepatitis B: Evolution over two decades.
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:138-43. doi: 10.1111/j.1440-1746.2010.06545.x.
7
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.
8
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Gastroenterology. 2009 Feb;136(2):486-95. doi: 10.1053/j.gastro.2008.10.026. Epub 2008 Nov 1.
9
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Gastroenterology. 2006 Dec;131(6):1743-51. doi: 10.1053/j.gastro.2006.09.020. Epub 2006 Sep 20.
10
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med. 2006 Mar 9;354(10):1011-20. doi: 10.1056/NEJMoa051287.
Zotero 插件